Dr. Abdul H. Mansoor

Hematology Oncology | Hematology
Kaiser Permanente
Interstate Medical Office Central
3600 N Interstate Ave, 
Portland, OR 
Accepting New Patients
Kaiser Permanente
Interstate Medical Office Central
3600 N Interstate Ave, 
Portland, OR 

Overview

Abdul Mansoor is a Hematologist Oncology specialist and a Hematologist practicing medicine in Portland, Oregon.

His clinical expertise encompasses Febrile Neutropenia, Chronic Familial Neutropenia, Agranulocytosis, Bone Marrow Aspiration, and Lymphadenectomy.

He is actively involved in clinical research, co-authoring 5 peer reviewed articles and participating in 30 clinical trials. Dr. Mansoor is currently accepting new patients.

Specialties

Hematology Oncology
Hematology

Licenses

Internal Medicine in OR

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser
  • EPO
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

Interstate Medical Office Central
3600 N Interstate Ave, Portland, OR 97227

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

30 Clinical Trials

Exceptional Responders Pilot Study: Molecular Profiling of Tumors From Cancer Patients Who Are Exceptional Responders
Exceptional Responders Pilot Study: Molecular Profiling of Tumors From Cancer Patients Who Are Exceptional Responders
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Drug
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2/Phase 3
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Drug
Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 2
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
View 9 Less Clinical Trials

5 Total Publications

Care Coordination for Mosunetuzumab Therapy in Patients With Follicular Lymphoma in Community Practices: Learnings From the MorningSun Study Investigators.
Care Coordination for Mosunetuzumab Therapy in Patients With Follicular Lymphoma in Community Practices: Learnings From the MorningSun Study Investigators.
Journal: Cancer medicine
Published: January 28, 2025
Similar Doctors
Expertise in
17
conditions
Dr. Michael Heinrich
Hematology
Expertise in
17
conditions
Dr. Michael Heinrich
Hematology

OHSU Hospital

3181 SW Sam Jackson Park Rd, 
Portland, OR 
 (15.8 miles away)
503-494-6594
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michael Heinrich is a Hematologist practicing medicine in Portland, Oregon. Dr. Heinrich is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Gastrointestinal Stromal Tumor, Chronic Myelogenous Leukemia (CML), Mesenchymoma, and Undifferentiated Pleomorphic Sarcoma.

Expertise in
39
conditions
Dr. Mei Q. Dong
Hematology Oncology | Hematology | Oncology
Expertise in
39
conditions
Dr. Mei Q. Dong
Hematology Oncology | Hematology | Oncology

Legacy Salmon Creek Hospital

700 Ne 87th Ave, Suite 360, 
Vancouver, WA 
 (7.7 miles away)
360-896-7070
Languages Spoken:
English, Mandarin
See accepted insurances
Accepting New Patients
Offers Telehealth

Mei Dong is a Hematologist Oncology specialist and a Hematologist practicing medicine in Vancouver, Washington. Dr. Dong is highly rated in 39 conditions, according to our data. Her clinical expertise encompasses Familial Colorectal Cancer, Pancreatic Cancer, Familial Pancreatic Cancer, and Primitive Neuroectodermal Tumor (PNET). Dr. Dong is currently accepting new patients.

Expertise in
27
conditions
Dr. Richard Maziarz
Hematology
Expertise in
27
conditions
Dr. Richard Maziarz
Hematology

OHSU Hospital

3181 SW Sam Jackson Park Rd, 
Portland, OR 
 (15.8 miles away)
503-494-5058
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Richard Maziarz is a Hematologist practicing medicine in Portland, Oregon. Dr. Maziarz is highly rated in 27 conditions, according to our data. His clinical expertise encompasses B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Abdul H. Mansoor

How do I make an appointment with Dr. Abdul H. Mansoor?

You can book an appointment with Dr. Abdul H. Mansoor by calling their office at 800-813-2000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Abdul H. Mansoor a top-rated expert for Febrile Neutropenia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Abdul H. Mansoor is classified as an Experienced expert for Febrile Neutropenia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Abdul H. Mansoor specialize in?

While Dr. Abdul H. Mansoor is a Hematology Oncology, they have specific expertise in Febrile Neutropenia, Chronic Familial Neutropenia, and Agranulocytosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Abdul H. Mansoor participate in research or clinical trials?

Yes. Dr. Abdul H. Mansoor has published 5 articles and abstracts on conditions like Febrile Neutropenia. You can view a list of Dr. Abdul H. Mansoor's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Abdul H. Mansoor accept my insurance?

Dr. Abdul H. Mansoor accepts most major insurance plans, including Aetna and HMSA. We recommend calling the office directly at 800-813-2000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mansoor's expertise for a condition
ConditionClose
        View All 28 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile